Evotec Se Quick Ratio (EVO) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Evotec Se  (NASDAQ: EVO)

Evotec Se's Quick Ratio

EVO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 1.01 a new company low.

Within Major Pharmaceutical Preparations industry 356 other companies have achieved higher Quick Ratio than Evotec Se in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 1843 to 1860.

Explain Quick Ratio?
How much Cash & cash equivalents EVO´s has?
What are EVO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVO Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -7.58 % -7.58 % -7.58 % -7.58 % -25.83 %
Y / Y Cash & cash equivalent Change -7.58 % -7.58 % -7.58 % -7.58 % -41.13 %
Quick Ratio MRQ 1.01 1.01 1.01 1.01 1.01
EVO's Total Ranking # 1860 # 1843 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % -7.58 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -7.58 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 357
Healthcare Sector # 641
Overall Market # 1860


Quick Ratio Statistics
High Average Low
1.98 1.35 1.01
(Dec 31 2021)   (Dec 31 2024)




Financial Statements
Evotec Se's Current Liabilities $ 357 Millions Visit EVO's Balance sheet
Evotec Se's Cash & cash equivalent $ 360 Millions Visit EVO's Balance sheet
Source of EVO's Sales Visit EVO's Sales by Geography


Cumulative Evotec Se's Quick Ratio

EVO's Quick Ratio for the trailling 12 Months

EVO Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -7.58 % -13.24 % -18.06 % -22.21 % -25.83 %
Y / Y Cash & cash equivalent TTM Growth -7.58 % -19.71 % -28.7 % -35.62 % -41.13 %
Quick Ratio TTM 1.01 1.01 1.01 1.01 1.01
Total Ranking TTM # 3725 # 3655 # # #
Seq. Current Liabilities TTM Growth -2.01 % -1.97 % -1.93 % -1.9 % -8.01 %
Seq. Cash & cash equivalent TTM Growth -2.01 % -1.97 % -1.93 % -1.9 % -14.87 %

Quick ratio ranking by company, industry and sector >> Back to EVO Financial Strength Comparisons >> Go to Compare EVO Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in EVO's Current Liabilities to $356.68 millions, cumulative Quick Ratio to 1.01 below the EVO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 433 other companies have achieved higher Quick Ratio than Evotec Se. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3655 to 3725.

Explain Quick Ratio?
How much Cash & cash equivalents EVO´s has?
What are EVO´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 434
Healthcare Sector # 889
Within the Market # 3725


trailing twelve months Quick Ratio Statistics
High Average Low
1.98 1.29 1.01
(Dec 31 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Biohaven Ltd   2.75 $ 319.137  Millions$ 115.934  Millions
Foghorn Therapeutics Inc   2.66 $ 158.894  Millions$ 59.738  Millions
Sol gel Technologies Ltd   2.63 $ 23.909  Millions$ 9.082  Millions
Bio Green Med Solution Inc   2.63 $ 3.505  Millions$ 1.332  Millions
Precigen Inc   2.62 $ 97.858  Millions$ 37.306  Millions
Avenue Therapeutics Inc   2.60 $ 2.855  Millions$ 1.099  Millions
Acadia Pharmaceuticals Inc   2.57 $ 819.686  Millions$ 318.692  Millions
Arbutus Biopharma Corp  2.56 $ 18.095  Millions$ 7.081  Millions
Genelux Corporation  2.52 $ 14.595  Millions$ 5.798  Millions
Xilio Therapeutics Inc   2.50 $ 137.531  Millions$ 54.930  Millions
Beone Medicines Ltd   2.49 $ 4,547.530  Millions$ 1,828.830  Millions
Processa Pharmaceuticals Inc   2.48 $ 5.537  Millions$ 2.236  Millions
Nextcure Inc   2.46 $ 25.982  Millions$ 10.566  Millions
Scienture Holdings Inc   2.44 $ 6.662  Millions$ 2.735  Millions
Hyperion Defi inc   2.39 $ 6.443  Millions$ 2.701  Millions
Nuvectis Pharma inc   2.38 $ 31.634  Millions$ 13.296  Millions
Seres Therapeutics Inc   2.37 $ 45.766  Millions$ 19.322  Millions
Satellos Bioscience Inc   2.35 $ 9.804  Millions$ 4.177  Millions
Insmed Inc  2.31 $ 1,430.047  Millions$ 618.925  Millions
Actuate Therapeutics Inc   2.31 $ 13.159  Millions$ 5.707  Millions
Elicio Therapeutics Inc   2.29 $ 18.563  Millions$ 8.110  Millions
Lantern Pharma Inc   2.29 $ 10.119  Millions$ 4.423  Millions
Regeneron Pharmaceuticals Inc   2.26 $ 8,605.200  Millions$ 3,815.400  Millions
Ultragenyx Pharmaceutical Inc   2.24 $ 680.000  Millions$ 303.000  Millions
Corcept Therapeutics Inc  2.24 $ 372.152  Millions$ 166.085  Millions
Petros Pharmaceuticals inc   2.24 $ 5.137  Millions$ 2.293  Millions
Galectin Therapeutics Inc   2.22 $ 17.726  Millions$ 7.967  Millions
Prf Technologies Ltd   2.22 $ 5.207  Millions$ 2.348  Millions
Filana Therapeutics Inc   2.20 $ 95.502  Millions$ 43.470  Millions
Mustang Bio inc   2.18 $ 17.266  Millions$ 7.914  Millions

Date modified: 2026-07-07T10:39:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.